Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
HARP: 145% | Bloomberg Reported Earlier: Merck Is In Advanced Talks To Buy Harpoon Therapeutics For ~$23/Share
ACON: 130% | Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan